Strattera and MAOIs: Why This Combination Is Contraindicated

Strattera (atomoxetine) and MAOIs (monoamine oxidase inhibitors) is one of the few drug combinations in psychiatry classified as absolute contraindication — never to be combined under any circumstances. The interaction can produce hypertensive crisis (severe potentially fatal blood pressure elevation) and serotonin syndrome (potentially fatal neurological emergency). Both mechanisms involve excessive accumulation of catecholamines (norepinephrine particularly) when atomoxetine's NE reuptake inhibition combines with MAOI's blockade of NE breakdown. The combination requires 14-day washout periods in BOTH directions — stopping MAOI before starting Strattera, and stopping Strattera before starting MAOI. This isn't a "use with caution" warning — it's an absolute prohibition that all prescribers, patients, pharmacists, and emergency personnel must understand.

This guide provides critical safety information about the Strattera-MAOI contraindication. We address why this combination is absolutely banned with the underlying pharmacological mechanisms, the hypertensive crisis emergency that combination can produce, the serotonin syndrome that may also occur, specific MAOI medications to know about including non-psychiatric MAOIs that patients might not recognize, the required 14-day washout periods in both directions of switching, emergency steps if combination occurred accidentally, safe antidepressant alternatives compatible with Strattera, four MAOI type classifications, the comprehensive MAOI medication inventory covering psychiatric MAOIs and hidden MAOIs (selegiline, linezolid antibiotic), the washout timeline visualization, and the bottom-line absolute safety guidance. This is the most serious drug-drug interaction in the Strattera safety series — understanding it can prevent fatal outcomes.

🛑 Why MAOIs + Strattera Is Banned

The pharmacological basis for the absolute contraindication:

• MAOIs block monoamine oxidase — enzyme that breaks down norepinephrine, serotonin, dopamine, and tyramine.
• Strattera blocks norepinephrine reuptake — preventing NE from being recycled out of synapses.
• Combination effect: NE accumulates massively in synapses — MAOI prevents breakdown, atomoxetine prevents reuptake.
• Catecholamine surge: Excessive NE produces dramatic sympathetic nervous system activation.
• Hypertensive crisis result: Severe BP elevation potentially fatal.
• Additional serotonin syndrome risk: If MAOI also affects serotonin, accumulated 5-HT produces serotonin syndrome.

The contraindication is enshrined in:

• FDA prescribing information for Strattera explicitly contraindicates MAOIs.
• Drug interaction databases universally flag this combination as Category X (avoid).
• Pharmacy dispensing systems typically alert pharmacists.
• Medical training emphasizes this absolute contraindication.
• Clinical guidelines from psychiatric organizations.

Why no exceptions are made:

• Risk is real and severe: Hypertensive crisis can cause stroke, MI, death.
• No therapeutic benefit outweighs the risk.
• Alternative medications available for both ADHD and depression.
• Even short combination dangerous: Single doses combined can produce crisis.
• Patient safety primary concern.

📈 Hypertensive Crisis: The Mechanism

Hypertensive crisis from MAOI-atomoxetine combination:

• Mechanism: Excessive synaptic NE produces extreme alpha-1 adrenergic stimulation, causing intense vasoconstriction and BP elevation.
• BP elevation magnitude: Can reach 220+/120+ mmHg — well above emergency threshold.
• Onset: May occur within hours of combined exposure or single dose.
• Severity range: Mild hypertensive urgency to severe hypertensive emergency with end-organ damage.
• Potential consequences: Stroke (hemorrhagic), myocardial infarction, aortic dissection, renal failure, encephalopathy, death.

Hypertensive crisis symptoms to recognize:

• Severe headache — often "worst headache of life" quality.
• Palpitations or chest pain.
• Severe anxiety or agitation.
• Nausea and vomiting.
• Sweating profusely.
• Visual changes — blurry vision, vision loss.
• Confusion or altered mental status.
• Shortness of breath.
• Stiff neck.
• Severe hypertension on BP measurement.

Emergency management:

• Call 911 or go to emergency department immediately.
• Inform emergency staff about both medications.
• Treatment includes IV antihypertensives (phentolamine, nicardipine, labetalol).
• BP must be lowered carefully — too rapid lowering can cause ischemic injury.
• Hospital admission likely for monitoring and continued treatment.
• Discontinuation of both medications.

🌡️ Serotonin Syndrome Risk

Serotonin syndrome potential from combination:

• Mechanism: Some MAOIs increase serotonin in addition to NE. Combined with any 5-HT activity from atomoxetine, can produce excess serotonergic activity.
• Atomoxetine's serotonin effect: Minimal direct serotonergic activity but increased with MAOI present.
• Spectrum of severity: Mild (tremor, hyperreflexia) to severe (high fever, multi-organ failure, death).
• Symptom triad: Cognitive changes + neuromuscular changes + autonomic instability.

Serotonin syndrome symptoms:

• Cognitive: Confusion, agitation, restlessness, hallucinations.
• Neuromuscular: Tremor, muscle rigidity, hyperreflexia, clonus, myoclonus.
• Autonomic: Hyperthermia, tachycardia, hypertension or hypotension, diaphoresis, mydriasis, diarrhea.
• Severe: Seizures, rhabdomyolysis, multi-organ failure, death.

Emergency management of serotonin syndrome:

• Stop offending medications immediately.
• Supportive care: Cooling, hydration, sedation (benzodiazepines).
• Cyproheptadine antidote for moderate-severe cases.
• ICU care for severe cases.
• Rhabdomyolysis monitoring.

📋 Specific MAOIs to Avoid

Comprehensive list of MAOIs that cannot be combined with Strattera:

Psychiatric MAOIs (depression treatment):

• Phenelzine (Nardil): Irreversible non-selective MAOI for depression. Used for treatment-resistant depression.
• Tranylcypromine (Parnate): Irreversible non-selective MAOI. Used for treatment-resistant depression.
• Isocarboxazid (Marplan): Irreversible non-selective MAOI. Less commonly used.
• Selegiline transdermal (Emsam patch): Selective MAOI-B at low doses but loses selectivity at higher doses. Used for depression at transdermal doses.

Parkinson's MAOIs:

• Selegiline oral (Eldepryl, Zelapar): MAOI-B selective at standard doses but may lose selectivity at higher doses.
• Rasagiline (Azilect): MAOI-B selective.
• Safinamide (Xadago): MAOI-B selective.

Hidden MAOIs (patients may not recognize):

• Linezolid (Zyvox): Antibiotic with weak MAOI activity. Important — used for serious bacterial infections; combination risk often unrecognized.
• Methylene blue (intravenous): Used in surgery for some indications; has MAOI activity.
• Procarbazine (Matulane): Chemotherapy with MAOI activity.

Considerations for each category:

• Irreversible MAOIs (phenelzine, tranylcypromine, isocarboxazid): Require 14-day washout because new enzyme synthesis takes ~14 days; permanent blockade until enzyme regenerated.
• Selegiline: Selective MAOI-B at low doses but loses selectivity at high transdermal doses. 14-day washout for combination changes.
• Rasagiline and safinamide: MAOI-B selective; theoretical lower interaction risk but contraindication still applies per labeling.
• Linezolid: Reversible; activity persists during treatment course; washout shorter (5-7 days typical).
• Methylene blue: Acute MAOI activity during IV infusion period.

🗓️ Required Washout Periods (14 Days Both Ways)

The mandatory washout periods:

Stopping MAOI before starting Strattera:

• 14-day washout required after MAOI discontinuation before starting Strattera.
• Reason: Irreversible MAOIs require new enzyme synthesis (~14 days) before MAO function returns.
• For selegiline: May require shorter washout (5 days) for selective MAOI-B at low doses; check specific guidance.
• For linezolid: Shorter washout (typically 5-7 days) due to reversible mechanism.
• For methylene blue: Wait for clearance of IV dose.

Stopping Strattera before starting MAOI:

• 14-day washout typically also required for atomoxetine clearance.
• Atomoxetine plasma clearance: 5-7 days for drug; additional time for receptor adaptation reversal.
• Conservative approach: 14-day washout matches MAOI side and ensures adequate safety margin.
• Some guidance: 5-day washout from Strattera may be acceptable in some clinical contexts.

Why 14 days specifically:

• Irreversible MAOI enzyme regeneration: Takes ~2 weeks for body to synthesize new MAO enzyme.
• Conservative safety margin: Allows for individual variation in clearance.
• FDA labeling standard: Universally specified period for MAOI transitions.
• Same approach as MAOI + other contraindicated drugs: Standard psychiatric pharmacology approach.

Practical considerations:

• Patient education important: Patients on MAOI may not realize Strattera is contraindicated.
• Treatment gap during washout: Patient unmedicated for ADHD during washout — plan accordingly.
• Pharmacy alert systems: Should flag attempted contraindicated combination.
• Specialist coordination: Switching between MAOI and Strattera generally specialist territory.

🆘 If You Took Them Together: Emergency Steps

What to do if combination occurred accidentally:

Immediate steps (within hours of combination):

1. Don't take next dose of either medication.
2. Monitor for symptoms of hypertensive crisis or serotonin syndrome.
3. Contact prescriber and/or poison control (1-800-222-1222 in US) for guidance.
4. If any concerning symptoms develop: Call 911 or go to emergency department.
5. Have both medication bottles available for medical staff.

Symptoms requiring emergency response:

• Severe headache (especially "worst headache of life").
• Severe chest pain or palpitations.
• Severe agitation or confusion.
• High fever (hyperthermia).
• Muscle rigidity, tremor, hyperreflexia.
• Profuse sweating.
• Severe hypertension if BP measured.
• Visual disturbances.
• Stiff neck.
• Loss of consciousness.

Emergency department management:

• BP measurement and continuous monitoring.
• ECG and cardiac monitoring.
• IV access for medications.
• Antihypertensives if hypertensive crisis: Phentolamine (specific for catecholamine-induced HTN), nicardipine, labetalol.
• Benzodiazepines for agitation.
• Cooling for hyperthermia.
• Cyproheptadine for moderate-severe serotonin syndrome.
• Supportive care: Fluids, electrolytes, monitoring.
• Hospital admission for continued monitoring.

What to tell ER staff:

• Specific medications taken — names and doses.
• Time of last dose of each medication.
• Duration of combined exposure — single dose or multiple doses.
• Current symptoms.
• Medical history including all medications.
• "Strattera and MAOI is contraindicated combination — risk of hypertensive crisis and serotonin syndrome."

✅ Safe Alternatives

Safe antidepressant alternatives compatible with Strattera:

For depression treatment alongside Strattera, consider:

• Escitalopram (Lexapro): Minimal CYP2D6 inhibition; standard Strattera dose compatible.
• Citalopram (Celexa): Minimal CYP2D6 inhibition; standard Strattera dose compatible.
• Sertraline (Zoloft): Mild CYP2D6 effect; slight Strattera adjustment may be needed.
• Venlafaxine (Effexor): Minimal CYP2D6 effect; SNRI alternative to MAOIs.
• Duloxetine (Cymbalta): Moderate CYP2D6 effect; requires Strattera dose adjustment.
• Mirtazapine (Remeron): Minimal CYP2D6 effect; useful for sleep/appetite.
• Trazodone: Often used for sleep; minimal interaction.
• Vilazodone (Viibryd): Newer SSRI/5-HT1A; minimal interaction.
• Vortioxetine (Trintellix): Multimodal; minimal interaction.

For comprehensive SSRI/SNRI interaction details, see Strattera and SSRI/SNRI Antidepressants.

For ADHD treatment if MAOI required for depression:

• Patient on MAOI may need alternative ADHD treatment.
• Stimulants also contraindicated with MAOIs (similar mechanism concern).
• Intuniv (guanfacine) or Kapvay (clonidine): Alpha-2 agonists; not contraindicated with MAOIs.
• Wellbutrin (bupropion): Contraindicated with MAOIs.
• Behavioral interventions for ADHD without medication options.
• Specialist consultation for complex situation.

When MAOI absolutely required (treatment-resistant depression):

• Patient cannot take Strattera concurrent.
• Discontinue Strattera with proper washout before starting MAOI.
• Choose ADHD treatment compatible with MAOI: Intuniv, Kapvay, or behavioral interventions.
• Address MAOI dietary restrictions (tyramine-containing foods).
• Specialist (psychiatrist) management essential.

🏷️ MAOI Type Classification

Four MAOI categories patients should recognize:

Type 1 — "Irreversible Non-Selective MAOIs (Psychiatric)." Phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan). Standard psychiatric MAOIs for depression. Permanent enzyme blockade until new MAO synthesized; 14-day washout required. Strict tyramine dietary restrictions while on these.

Type 2 — "Selective MAOI-B (Parkinson's)." Selegiline (Eldepryl, oral; Emsam patch — depression), rasagiline (Azilect), safinamide (Xadago). Primarily for Parkinson's disease; selegiline transdermal also for depression. Selective for MAOI-B at standard doses but may lose selectivity at higher doses. Contraindication with Strattera still applies per labeling. Selegiline transdermal washout 14 days; oral selegiline 5-day washout possible at low doses.

Type 3 — "Hidden/Non-Psychiatric MAOIs." Linezolid (Zyvox antibiotic), methylene blue (IV surgical use), procarbazine (chemotherapy). Patients may not recognize these as MAOIs. Important to disclose all medications including antibiotics and chemotherapy to all prescribers. Linezolid washout 5-7 days; methylene blue acute exposure during infusion.

Type 4 — "Newer Reversible MAOIs (RIMAs)." Moclobemide (available in some countries; not US-approved). Reversible MAOI-A inhibition; theoretically lower interaction risk than irreversible MAOIs. Still contraindicated with Strattera per labeling. Shorter washout possible due to reversibility.

📋 Comprehensive MAOI Medication Inventory

Complete inventory of MAOIs to disclose to prescribers:

How to ensure all MAOIs disclosed:

• Bring all medication bottles to new prescriber appointments.
• Maintain comprehensive medication list updated regularly.
• Disclose ALL medications including antibiotics, chemotherapy, supplements.
• Pharmacist consultation for any new prescription on Strattera.
• Pharmacy alert systems should flag contraindications but don't rely solely on these.
• Emergency situations: Always tell ER staff about Strattera before any new medication administered.

📅 Washout Timeline Both Directions

Visual timeline of required washout periods:

Switching from MAOI to Strattera:

• Day 0: Last MAOI dose.
• Days 1-13: Wash-out period. No Strattera. Patient unmedicated for ADHD during this period.
• Day 14: Safe to start Strattera. Begin at appropriate starting dose; titrate per usual protocol.
• Considerations: Plan during low-demand period if possible; alternative ADHD coping during washout.

Switching from Strattera to MAOI:

• Day 0: Last Strattera dose.
• Days 1-13: Wash-out period. No MAOI. Patient may be on bridge medication or off all psychiatric medications.
• Day 14: Safe to start MAOI per usual MAOI initiation protocol.
• Considerations: MAOI typically for treatment-resistant depression; specialist coordination essential.

Variations by specific MAOI:

• Selegiline transdermal: 14 days washout.
• Selegiline oral low-dose: 5 days may be acceptable (selective MAOI-B).
• Rasagiline, safinamide: 14 days conservative; selective MAOI-B may allow shorter per specialist.
• Linezolid: 5-7 days (reversible).
• Methylene blue IV: Wait for acute clearance.

What can go wrong during washout:

• Patient impatience — wanting to start new medication sooner.
• ADHD symptom return during washout if previously controlled.
• Depression rebound when stopping MAOI.
• Adherence concerns if patient on MAOI takes Strattera too soon.
• Communication gaps between prescribers.

Strategies for successful washout:

• Patient education about reasons for washout period.
• Calendar reminders for safe restart date.
• Specialist coordination across psychiatrists if relevant.
• Bridge medication consideration if appropriate.
• Behavioral support during unmedicated period.
• Frequent contact with prescriber during washout.

✨ Bottom Line

Strattera and MAOIs is one of the most serious drug-drug interactions in psychiatry — absolute contraindication with potential for hypertensive crisis and serotonin syndrome, both potentially fatal. The combination is never appropriate under any circumstances. 14-day washout periods required in both directions of switching (5 days possible for some selective MAOIs like low-dose oral selegiline; 5-7 days for linezolid; 14 days for irreversible psychiatric MAOIs).

The mechanism involves catastrophic catecholamine accumulation — MAOI blocks NE breakdown, atomoxetine blocks NE reuptake, combined effect produces excessive sympathetic activation leading to severe BP elevation. Hypertensive crisis can develop within hours of combined exposure; BP elevations to 220+/120+ mmHg possible with potential for stroke, MI, aortic dissection, encephalopathy, death.

Serotonin syndrome additional risk when MAOI also affects serotonin. Symptom triad: cognitive changes + neuromuscular changes + autonomic instability. Severe cases include hyperthermia, multi-organ failure, death.

Comprehensive MAOI inventory includes psychiatric MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline transdermal), Parkinson's MAOIs (selegiline oral, rasagiline, safinamide), and hidden MAOIs (linezolid antibiotic, methylene blue IV, procarbazine chemotherapy). Patients must disclose ALL medications including antibiotics and chemotherapy to all prescribers.

The four MAOI type classifications (Irreversible psychiatric / Selective MAOI-B / Hidden non-psychiatric / Reversible RIMA) help patients and prescribers recognize all relevant medications. Pharmacist consultation valuable for complex situations.

Emergency response if combination occurred: don't take next dose, monitor for symptoms, contact prescriber/poison control, call 911 for concerning symptoms (severe headache, chest pain, agitation, fever, muscle rigidity, severe hypertension). Bring medication bottles to ER. Treatment includes IV antihypertensives, benzodiazepines, cyproheptadine for serotonin syndrome, supportive care, hospital admission.

Safe antidepressant alternatives for patients on Strattera who need depression treatment include SSRIs (escitalopram, citalopram, sertraline particularly compatible), SNRIs (venlafaxine, duloxetine with adjustments), and other agents (mirtazapine, trazodone, vilazodone, vortioxetine). See Strattera and SSRI/SNRI Antidepressants for comprehensive guidance.

When MAOI required for treatment-resistant depression: Strattera not compatible; consider alternative ADHD treatments (Intuniv, Kapvay, behavioral interventions). Wellbutrin and stimulants also contraindicated with MAOIs. Complex patients require specialist coordination.

For broader Strattera lifestyle/interaction context, see Strattera and Alcohol, Strattera and Caffeine, and Strattera and SSRI/SNRI.

For Strattera safety cluster: Long-Term Side Effects, Cardiovascular Effects (relevant for MAOI hypertensive crisis context), Liver Health, FDA Black Box SI, Sleep Effects, Weight Loss, Sexual Side Effects, Withdrawal.

For Strattera comparison cluster: vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin, vs Intuniv, vs Qelbree.

For modafinil as off-label ADHD alternative (also has MAOI contraindication — similar consideration), Modalert 200 mg from Sun Pharma provides Schedule IV option.

❓ Frequently Asked Questions

📚 References & Further Reading

• FDA prescribing information for Strattera (atomoxetine) — MAOI contraindication.
• FDA prescribing information for phenelzine, tranylcypromine, isocarboxazid, selegiline — MAOI labeling.
• FDA prescribing information for linezolid — MAOI activity disclosure.
• Boyer & Shannon, NEJM — serotonin syndrome review.
• American Heart Association — hypertensive emergency management guidelines.
• American Psychiatric Association — MAOI prescribing guidelines.
• Poison Control Centers — drug interaction emergency resources (1-800-222-1222 US).
• Drug Interaction Database (Lexicomp, Micromedex) — comprehensive interaction information.
• Strattera interaction cluster: Alcohol, Caffeine, SSRI/SNRI
• Strattera safety cluster: Long-Term, Cardiovascular, Liver Health, FDA Black Box SI, Sleep, Weight Loss, Sexual, Withdrawal
• Strattera comparison cluster: vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin, vs Intuniv, vs Qelbree
• Modalert 200 mg, Modvigil 200 mg, Waklert 150 mg — primary product pages.
• RXshop Editorial Team — content reviewed by licensed pharmacist; for adult patient education, not a substitute for individual medical consultation.